Enzon Pharmaceuticals, Inc.
ENZN
$0.0808
-$0.0048-5.61%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 0.00 | 26.00K | 26.00K | 26.00K | 26.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.00 | 26.00K | 26.00K | 26.00K | 26.00K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 0.00 | 26.00K | 26.00K | 26.00K | 26.00K |
| SG&A Expenses | 1.99M | 2.03M | 1.35M | 1.24M | 1.12M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.99M | 2.03M | 1.35M | 1.24M | 1.12M |
| Operating Income | -1.99M | -2.00M | -1.33M | -1.22M | -1.09M |
| Income Before Tax | -1.01M | 299.00K | 1.13M | 1.33M | 1.42M |
| Income Tax Expenses | 319.00K | 365.00K | 347.00K | -195.00K | -168.00K |
| Earnings from Continuing Operations | -1.33 | -0.07 | 0.78 | 1.52 | 1.59 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.33M | -66.00K | 778.00K | 1.52M | 1.59M |
| EBIT | -1.99M | -2.00M | -1.33M | -1.22M | -1.09M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.04 | -0.02 | -0.01 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 |
| EPS Diluted | -0.04 | -0.02 | -0.01 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 |
| Average Basic Shares Outstanding | 296.86M | 296.86M | 296.86M | 296.86M | 296.86M |
| Average Diluted Shares Outstanding | 296.86M | 296.86M | 296.86M | 296.86M | 296.86M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -95.72% | -1,931.82% | 163.88% | 83.77% | 80.24% |